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ABSTRACT
Cardiovascular disease (CVD) is a highly common complication
and the ﬁrst cause of death in patients with end-stage renal dis-
ease (ESRD) on haemodialysis (HD). In this population, mortal-
ity due to CVD is 20 times higher than in the general population
and the majority of maintenance HD patients have CVD. This is
likely due to ventricular hypertrophy as well as non-traditional
risk factors, such as chronic volume overload, anaemia, inﬂam-
mation, oxidative stress, chronic kidney disease–mineral bone
disorder and other aspects of the ‘uraemic milieu’. Better under-
standing the impact of these numerous factors on CVD would
be an important step for prevention and treatment. In this re-
view we focus non-traditional CVD risk factors in HD patients.
Keywords: cardiovascular disease, chronic kidney disease,
haemodialysis
INTRODUCTION
Cardiovascular disease (CVD) is the major cause of morbidity
and mortality in patients with end-stage renal disease (ESRD)
on haemodialysis (HD) [1, 2]. Since ESRD frequently results
from hypertension and diabetes mellitus, the increased CVD
risk in these patients has been assumed to be the result of these
underlying diseases. Nevertheless, it has been elucidated how
ESRD represents per se a CVD risk factor independently by
both hypertension and diabetes mellitus [1, 2].
CVD is present in>50% of patients undergoing dialysis and
the relative risk of death due to CVD events in HD patients is
reported to be 20 times higher than in the general population.
In fact, in patients on renal replacement therapy (RRT) the
prevalence of coronary heart disease and ventricular hypertro-
phy has been described to be 40% and 70%, respectively [3].
The prevalence of hypertension, a major risk factor for coronary
artery disease (CAD) and left ventricular hypertrophy (LVH) is
high in patients with chronic kidney disease (CKD) (87–90%).
At least 35% of patients with CKD have evidence of an ischae-
mic event (myocardial infarction or angina) at the time of pre-
sentation to a nephrologist. The prevalence of LVH increases at
each stage of CKD, reaching 75% at the time of dialysis
initiation, and the modifiable risk factors for LVH include anae-
mia and systolic blood pressure, which are also worse at each
stage of kidney disease.
Although there have been significant improvements in the
management of CVD in the general population, it is not known
if these interventions result in similar benefits for HD patients. In
addition, differences in the types, distribution, mortality and
pathophysiology of CVD in ESRD patients suggest that generali-
zation of data from patients without kidney disease should be ex-
trapolated with caution. CV risk factors among HD patients can
be divided into those that are non-specific to kidney disease but
are more prevalent and those that are specific to ESRD. There is
higher prevalence of many traditional factors for CV risk (age,
male gender, hypertension, diabetes, dyslipidaemia and physical
inactivity). Furthermore, HD patients have disease-related risk
factors such as anaemia, hyperhomocysteinaemia, chronic kidney
disease–mineral bone disorder (CKD-MBD), oxidative stress,
malnutrition and chronic inflammation. There is evidence that
uraemic factors may be implicated in the pathogenesis of CV dis-
ease in HD patients, since CV survival improves after kidney
transplantation even in high-risk patients [4, 5].
In this review we focus on non-traditional CV risk factors in
HD patients.
URAEMIC TOXINS AND CVD
With the decline of renal function, a large group of substances are
inadequately removed by the kidney: these are the uraemic toxins.
They are biologically active and are both cause and consequence
of CKD, with a detrimental effect on the CV system, possibly me-
diated by their impact on the functions of cells involved in myo-
cardial and vessel functions [leucocytes, endothelial cells (ECs),
smooth muscle cells, platelets] [6]. In fact, an inhibition of leuco-
cyte activity observed in HD patients may compromise infection
response and trigger a condition of micro-inflammation and con-
sequently atherosclerosis. Moreover, uraemic toxins induce an
enhancement of leucocyte oxidative activity, an up-regulation in
leucocyte–endothelial interactions and an infiltration of macro-
phages andmonocytes into vascular atherosclerotic lesions [3].
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p-Cresol is a metabolic product of aromatic amino acids
generated in the gut through the bacterial degradation of tyro-
sine and phenylalanine [7]. It is absorbed from the intestinal
tract and almost completely converted in its main metabolites,
p-cresylsulfate (pCS) and p-cresylglucuronide, two small mole-
cules significantly bound to plasma proteins. While healthy kid-
neys efficiently remove p-cresol, it tends to accumulate in CKD
patients, for two major reasons: because of the modifications of
gut microbiome in CKD and the inability of the failing kidney
to excrete it. High plasma concentrations of total p-cresol
strongly associate to CV risk in CKD and are predictive of mor-
tality [8, 9]. Since pCS remains difficult to remove by dialysis,
the gut microbiota could be a future target to decrease pCS lev-
els and its toxicity, even at earlier stages of CKD.
In vitro studies have demonstrated that p-cresol can cause
EC dysfunction through a toxic mechanism mediated by
Rho-kinase activity [10, 11]. Therefore therapeutic strategies to
reduce plasma p-cresol levels are needed. In vitro studies have
shown that sevelamer hydrochloride, a synthetic phosphate
binder widely used in dialysis patients, can also bind p-cresol
[12].
Another uraemic toxin is indoxyl sulphate (IS), which is
greatly accumulated in CKD and its concentration can increase
up to 50-fold compared with healthy people. IS results from
tryptophan metabolism and it has a high-affinity of binding to
albumins, a condition that hinders its removal by HD. It exerts
pro-oxidative and pro-inflammatory activity, triggers immune
response and stimulates the progression of CKD [13, 14].
The negative action of IS on the CV system seems to be con-
centration dependent. In CKD patients, IS induces a pro-oxida-
tive action leading to increased CVD, while in normal renal
function subjects, IS plays a potential protective role, eliminat-
ing hydroxyl radicals [3]. Several authors indicate a potential
role of IS in the progression of vascular damage, haemostatic
dysfunction and the progressive inflammatory process.
According to Shivanna et al. [15], Chitalia et al. [16] and
Kaminski et al. [17], IS is a potential CKD-related pro-throm-
botic uraemic toxin that induces tissue factor (TF) in vascular
smooth muscle cells (VSMCs) and increases post-vascular in-
terventional pro-thrombotic risk in a TF-dependent manner.
Therefore both IS and p-cresol increased their concentra-
tions in uraemic patients, inducing a reduction in endothelial
proliferation and negatively influencing cell repair processes
in vitro, both involved in atherosclerosis pathogenesis.
Furthermore, both IS and p-cresol are able to inhibit nitric ox-
ide (NO) production, which is decreased in CKD patients, and
to reduce EC viability by in vitro reactive oxygen species (ROS)
production.
Advanced glycation end products (AGEs), a group of com-
pounds formed by the ‘Maillard reaction’ between reducing
sugars and amino acids, lipids or DNA, are formed also in dis-
eases with high levels of oxidative stress, such as ESRD. In these
patients high levels of circulating AGEs result from increased
formation and decreased renal clearance. Interactions between
AGEs and their receptor AGEs (RAGEs) trigger various intra-
cellular events, such as oxidative stress and inflammation, lead-
ing to CV complications. Today there is a large body of
evidence showing that the interaction between AGEs and
RAGEs plays a key role in vascular damage, with special con-
cern for endothelial dysfunction and arterial stiffness [18].
OXIDATIVE STRESS , ENDOTHELIAL
DYSFUNCTION AND CVD
Oxidative stress is considered an imbalance in the ROS produc-
tion:degradation ratio. There is a lot of evidence that uraemia is
a pro-oxidant condition. Since kidney is one of the most impor-
tant sources of antioxidant enzymes, progressive loss of renal
function increases the level of pro-oxidant substances [3].
Oxidative stress is quite common in ESRD and contributes to
the progression of kidney damage by promoting renal ischae-
mia, by inciting glomerular injury, by inducing cell death and
by stimulating inflammation [19]. In addition, oxidative stress
gradually increases along with renal impairment and it is fur-
ther exacerbated by HD. Known oxidative molecules are ROS
and nitrogen species such as NO. The bioavailability of NO
largely contributes to endothelial dysfunction in many diseases
such as hypertension, atherosclerosis and diabetes. Asymmetric
dimethylarginine (ADMA) is an endogenous amino acid simi-














FIGURE 1: Cardiovascular disease in dialysis.
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synthase. ADMA is associated with impaired NO synthesis and
is considered a predictor of CV events and death both in ESRD
patients and in the general population [20]. Furthermore, EC
damage is related to diseases such hypertension, renal failure
and atherosclerosis and is considered responsible for acceler-
ated atherosclerosis in ESRD patients. Increased levels of
ADMA in ESRD due to a reduction in inactivation and elimina-
tion processes has been reported to be a novel risk factor for en-
dothelial dysfunction. High ADMA levels are associated with
endothelial dysfunction as well as with higher intima-media
thickness and CV events in ESRD. Moreover, Ravani et al. [21]
reported that high ADMA levels represent a strong indepen-
dent risk factor for progression of CKD and patient death.
Reduced NO synthesis by ECs due to accumulation of endoge-
nous inhibitors of the NOS such as ADMA has been implicated
in accelerating progression of endothelial dysfunction [22].
Recently Liakopoulos et al. [23] reported all conditions cor-
related to oxidative stress in HD patients. HD is characterized
by excessive oxidative stress due to loss of antioxidants during
procedures and to accumulation of oxidative products. It is
thought that HD promotes the formation of pro-oxidant reac-
tive oxygen molecules with a direct increase in plasma ROS lev-
els after each HD session [24, 25]. Interestingly, Bayes et al. [26]
found reduced serum vitamin E levels in HD patients, while
Morena et al. [27] reported that, compared with healthy con-
trols, patients undergoing chronic haemodiafiltration had sig-
nificantly lower plasma levels of vitamin C.
The HD process promotes the formation and accumulation
of oxidative products through activation of platelets, comple-
ment and polymorphonuclears. Two studies showed that
plasma ROS levels were significantly increased in HD patients
compared with healthy controls, a condition explained with the
prominent dysfunction of the mitochondrial respiratory system
in CKD and in HD patients [23].
CHRONIC INFLAMMATION AS A CV RISK
FACTOR
Chronic inflammation in CKD patients may be detected by
high levels of pro-inflammatory cytokines, such as interleukin-
6 (IL-6). In several studies it has been shown that plasma IL-6
levels are strong predictors of CV mortality in dialysis patients
[28]. Furthermore, it has been claimed that endogenousmethyl-
arginines, ADMA and symmetric dimethylarginine (SDMA)
and other methylarginines including L-NG monomethylargi-
nine (LNMMA) are contributing factors to inflammation. In
fact, high plasma ADMA levels are suggestive of endothelial
dysfunction and atherosclerosis in the general population.
ADMA is increased in ESRD and predicts mortality in this pop-
ulation. Moreover, ADMA increases IL-6 and tumour necrosis
factor-alpha (TNF-a) expression, and ADMA represents the
primary endogenous inhibitor of NO synthase, which leads to a
reduction in the bioavailability of NO [29]. Interestingly,
Emrich et al. [30] performed a study on blood samples from
528 patients with CKD Kidney Disease: Improving Global
Outcomes (KDIGO) classification G2–G4, looking for an asso-
ciation of elevated plasma levels of ADMA, SDMA, acetylated
ADMA, acetylated SDMA and LNMMA and atherosclerotic
CVD. In particular, CKD patients in the highest tertile of
plasma SDMA remained at highest risk for CKD progression
and atherosclerotic CV events.
PROTEIN CARBAMYLATION
Blood levels of urea rise with a progressive decline in kidney
function. Older studies suggested the non-toxicity of high blood
urea concentration after acute infusion, but some evidence of
direct and indirect toxicity of chronically high urea levels is
emerging [31]. Chronically high levels of urea cause alterations
in different target organs: (i) gastrointestinal epithelial barrier
breakdown with bacterial toxins passage, causing systemic in-
flammation; (ii) activation of protein carbamylation reaction
secondary to isocyanic acid dissociation, altering the structure
and function of proteins; (iii) CV atherosclerosis by carbamyla-
tion of low-density lipoprotein; (d) renal fibrosis due to carba-
mylation of albumin and (e) anaemia by erythropoietin
carbamylation. Carbamylation is linked to an increased CV risk
in ESRD patients. Intensification of HD therapy in RRT
patients may help in controlling low levels of plasma urea and




Cardiovascular calcifications (CVCs) are a well-known CV risk
factor in HD patients. In vitro studies have shown that the pro-
cess of vascular calcification does not consist of a simple deposi-
tion of calcium phosphate crystals, but appears to be an active
regulated process resembling bone osteogenesis [33]. The vas-
cular calcification process is complex and involves a transdiffer-
entiation of VSMCs into cells resembling bone progenitor cells.
These cells down-regulate the production of specific genes and
up-regulate the growth of osteochondrogenesis markers, losing
their contractile competence and acquiring collagenmatrix pro-
duction and forming calcium–phosphorus-rich vesicles able to
start the mineralization process of the vessel internal surface
[34]. In dialysis patients, CVC can increase the incidence of
arrhythmias, sudden cardiac death, stroke and mortality.
Calcified blood vessels lead to ischaemic CVD and increased
pulse pressure and pulse wave velocity (PWV), contributing to
the reduction of diastolic coronary perfusion and to LVH,
which is a well-known CV risk factor. Aortic stenosis, a fre-
quent consequence of calcification processes, increases cardiac
afterload, thus further contributing to LVH [35]. In a recent
meta-analysis, Wang et al. [36] confirmed that a higher degree
of CVC was associated with an increased risk of mortality and
that the number of calcified cardiac valves is correlated with the
mortality risk. The prevalence of aortic arch calcification ranged
from 23.27% to 57.60%, and in dialysis patients the presence of
CVC increased the risk of CV mortality by 181% and by 73%
for all-cause mortality. Moreover, patients in dialysis with two
calcified cardiac valves had a greater mortality risk, as revealed
by a subgroup analysis. This study also provides evidence that
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the detection of valve calcification is fundamental for risk strati-
fication of dialysis.
Computed tomography (CT) is the gold standard for evalua-
tion of vascular calcification, but plain radiographs could offer a
less costly alternative with less radiation exposure, given also
that the KDIGO guidelines suggest the use of lateral abdominal
radiograph to detect the presence or absence of vascular calcifi-
cation in CKD Stage 3–5 patients as a reasonable alternative to
CT-based imaging [37]. In addition to lateral abdominal radio-
graphs, plain radiographs of chest, pelvis, both hands and
feet can also be utilized to evaluate calcification of the aortic
arch, iliac arteries, femoral arteries and small arteries of the
hands and feet.
Dimkovic et al. [38] conducted a longitudinal observational
study, the aim of which was to assess CV mortality in HD
patients with different baseline composite calcification scores,
where composite calcification scores were determined by com-
bining ultrasound (Adragao X-ray score) and X-ray analyses
(X-ray score of the arteriovenous fistula). In patients dying
from CVD, composite and Adragao calcification scores were
significantly higher, as was PWV compared with survivors.
Moreover, a post hoc analysis confirmed that deceased patients
had significantly lower serum fetuin-A, osteoprotegerin (OPG),
and haemoglobin, but higher C-reactive protein (CRP) levels as
compared with surviving patients. The authors noted a relation-
ship between PWV and the degree of vascular calcification.
Although this relation is still a matter of debate, stiffened arter-
ies may have a significant impact on CV remodelling, leading to
LVH, which could contribute to heart failure and/or sudden
cardiac death.
Since the Framingham risk score poorly predicts CV events
in HD patients, several CKD-MBD biomarkers, such as fetuin-
A, OPG and osteopontin, have been associated with vascular
calcification [37, 39].
OPG is a soluble cytokine of the TNF-receptor superfamily
expressed in osteoblasts, ECs, VSMCs or the myocardium. It is
modulated by inflammatory cytokines and inhibits osteoclast
differentiation and activity and for this reason it is called a
‘bone protector’. Osteogenic markers including OPG are sug-
gested to play an important role in the mineralization of ectopic
sites and are linked to vascular calcification. Although OPG is
suggested to have an active role in vascular pathophysiology, it
is not currently clear whether this role is beneficial or injurious
to the vasculature. Fetuin-A is a circulating glycoprotein se-
creted by the hepatocytes. It acts as a potent systemic inhibitor
of calcification and a negative acute phase reactant. In HD
patients, plasma fetuin-A levels are lower than in healthy con-
trols and associated with severe and extensive vascular calcifica-
tion and arterial stiffness, as well as with increased all-cause and
CVmortality [39].
Collado et al. [40] tried to assess whether serum OPG and/or
fetuin-A predict mortality and CV morbidity and mortality in
HD patients, as well as their association with atherosclerosis
and/or vascular calcification and with cardiac structure and
function. The presence of carotid atherosclerotic disease, de-
fined by a pathological intima-media thickness and/or presence
of carotid plaques with stenosis or calcified atherosclerotic
plaques was associated with higher OPG levels but not with
fetuin-A levels. These results provide additional evidence, as
well as a recent meta-analysis that reported an increased mor-
tality risk associated with higher OPG levels [41, 42]. It is still
not clear whether OPG is causally related to atherosclerosis or
is a marker of the atherosclerotic burden. Despite that higher
OPG levels have also been associated with an increased CV risk
in the general population, drugs targeting the receptor activator
of nuclear factor jb (RANK)–RANK ligand–OPG axis have
not been associated with an effect on CV events in randomized
controlled trials in the general population.
FIBROBLAST GROWTH FACTOR-23 , KLOTHO
AND CVD
Fibroblast growth factor-23 (FGF23) is a protein primarily se-
creted by bone tissue (osteoclasts and osteocytes) that regulates
phosphate excretion together with parathyroid hormone (PTH)
via interaction with FGF receptors. Physiologically FGF23
requires the presence of coreceptor a-Klotho to perform its ac-
tivity. The Klotho gene encodes a single-pass transmembrane
protein expressed in multiple tissues but is found at particularly
high levels in the kidney. Clearly Klotho and FGF23 interplay to
participate in mineral homeostasis [43, 44]. In fact, FGF23
exerts its effects at the level of proximal and distal kidney
tubules, where it inhibits the sodium–phosphate co-transporter
mechanism in a modality resembling PTH action, resulting in a
phosphaturic effect and in sodium storage that leads to develop-
ment of hypervolaemia and potentially hypertension.
FGF23 reduces phosphorus levels by inhibiting the synthesis
of 1,25-hydroxyvitamin D and by suppressing PTH synthesis in
the parathyroid glands, probably in a Klotho-dependent man-
ner [3]. In CKD patients, levels of FGF23 increase early in the
course of kidney disease already in Stage 2, earlier than both
phosphorus and PTH increases [44]. Klotho and FGF23 might
be novel diagnostic targets for the early diagnosis of renal dys-
function and prediction of chronic complications, including
CVD in ESRD. In ESRD, FGF23 reaches levels 100 times the
physiological values. According to some studies, an elevated
plasma FGF23 concentration is independently associated with
an increased risk of CKD progression, CV complications and
mortality in ESRD. In addition, in the general population,
FGF23 plasma levels in coronary patients were associated with
a higher risk of death and CV, even after adjustment for con-
founding factors.
Elevated FGF23 levels were independently associated with
LVH in a large CKD cohort. FGF23 caused pathological
hypertrophy of isolated rat cardiomyocytes via FGF receptor–
dependent activation of the calcineurin–nuclear factor of
activated T cells signalling pathway, but this effect was indepen-
dent of a-klotho [45].
As reported by Cozzolino and Mazzaferro [46], soluble
Klotho is dramatically decreased in CKD and ESRD. Klotho de-
ficiency and FGF23 elevation are associated with poor out-
comes and complications in CKD/ESRD patients. They have
also been proposed as sensitive biomarkers for adverse renal
and extrarenal outcomes in patients with CKD and ESRD.
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Accumulating evidence from animal experiments has shown
that Klotho deficiency causes vascular calcification, cardiac fi-
brosis and cardiac hypertrophy in CKD [47, 48]. A cross-
sectional study of CKD patients with a modest decline in renal
function revealed that serum Klotho is independently associ-
ated with arterial stiffness measured by ankle–brachial PWV
[49]. Moreover, decreased Klotho production renders the kid-
ney more susceptible to a variety of kidney insults and exacer-
bates uraemic cardiomyopathy and vascular calcification.
GUT MICROBIOME (GM) AS A POTENTIAL
SOURCE OF URAEMIC TOXINS
The GM performs a multitude of functions and can be consid-
ered a metabolically active endogenous organ. Dysbiosis is the
alteration of the human microbiota composition in a given site
and can stimulate pro-inflammatory cytokine production and
foam cells formation. This generates a ring reaction in which in-
flammation can induce oxidative stress and the latter in turn
increases the inflammatory state [50]. The possible breaking of
the intestinal barrier (epithelial tight junctions) can lead to the
translocation of bacteria and endotoxins in the circulatory sys-
tem, inducing inflammation. HD itself may induce intestinal is-
chaemia during hypotension with alteration of intestinal wall
integrity. Evidence indicates a relationship between host and
the altered microbiota in animals and humans with CKD.
Many authors have described an important change in the struc-
ture and function of GM in humans and animals with advanced
CKD; these studies showed a clear reduction in the
Bifidobacterium spp.:Enterobacteriaceae ratio. Changes in the
microbiota composition produce excessive quantities of urae-
mic toxins such as p-cresol sulphate, IS and trimetylamine-N-
oxide, but fewer metabolites with a protective role in inflamma-
tion, oxidative stress, fibrosis and kidney diseases progression
[50]. Gut-derived uraemic toxins contribute to the progression
of CKD as well as CVD: the Eutox group showed that an ele-
vated level of IS is associated with vascular stiffness, aortic calci-
fication and higher CV mortality. Free serum levels of p-cresol
are associated with CVmortality in dialysis patients [3].
ACIDOSIS AND CVD
Excretion of the acid produced by metabolism is mainly accom-
plished by two pathways: the lungs, responsible for eliminating
volatile acids, and the kidneys, for the non-volatile acids.
Metabolic acidosis is a common condition in ESRD patients, due
to a decreased ability to excrete non-volatile acid and reduced re-
nal synthesis of bicarbonate. It leads to malnutrition, inflamma-
tion, bone disease disorders and even a higher death risk [51].
Major acid–base variations during dialysis and the imbalan-
ces in serum calcium levels intensified by them play a role in
CVD in HD patients. There is a significant positive association
of metabolic acidosis status with high-sensitivity CRP serum
concentrations. The aim of the study by Raikou and Kyriaki
[52] was the association between low serum bicarbonate con-
centrations and CVD in patients on intermittent dialysis. They
found that metabolic acidosis status was significantly associated
with the existence of both peripheral vascular disease and
diastolic dysfunction. However, they did not find that the low
bicarbonates were an independent risk factor for diastolic dys-
function after adjustment for covariates and they found no sig-
nificant association between low bicarbonate and systolic
cardiac disorder or coronary artery disease. Another prospec-
tive study of Voiculet; et al. [53] highlighted the repercussions of
low levels and variation in serum bicarbonate on bone mineral
metabolism parameters, as well as on vascular stiffness and the
vascular calcification process in chronic HD patients. Although
HD is the most important method of correction for the meta-
bolic acidosis of ESRD patients, the changes in serum bicarbon-
ate levels produced by a dialysis session are sometimes too
abrupt and tempestuous, producing adverse consequences. A
statistically significant association has been found between dial-
ysis bicarbonate, average serum calcium levels and serum phos-
phorus, as well as PWV mean values and the number of
vascular calcifications. It is important to avoid large variations
in serum bicarbonate levels in HD patients because these varia-
tions can increase vascular stiffness, vascular calcification and,
in general, CV risk.
CONCLUSIONS AND PERSPECTIVES
Numerous other risk factors involved in the pathogenesis of
CVD in dialysis patients are not included in this review. In par-
ticular, there is evidence that intradialytic volume overload can
affect the development of LVH and cardiac failure. Fluctuations in
plasma levels of sodium, potassium, calcium and magnesium dur-
ing HD treatment may trigger life-threatening cardiac arrhyth-
mias. Moreover, hypotension during dialysis can induce ischaemic
events in different organs and tissues, such as the myocardium, gut
and central nervous system, even if clinically undetectable. Today,
other factors are under investigation in ESRD patients, such as car-
diotonic steroids (CTS), a new class of hormones with the ability
to bind and inhibit the ubiquitous Naþ/Kþ transport enzyme
pump. Serum levels of ouabain, telocinobufagin and marinobufa-
genin are substantially elevated in patients with ESRD. There is
some evidence that chronic exposure to CTS can contribute to
CVD development characterized by LVH, fibrosis, diastolic dys-
function, arrhythmias and a reduction in ejection fraction [54].
Considering the high burden that CVD has in HD patients,
additional studies are needed to improve the treatment of this
condition. CVD is very common in HD patients and causes a
high risk of mortality. There are a lot of nontraditional factors
that contribute to worsen this condition. A better understand-
ing of these through clinical and experimental studies is neces-
sary to try to improve life in HD patients and to reduce their
elevated risk of CVmorbidity andmortality.
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